COX-2 is associated with proliferation and apoptosis markers and serves as an independent prognostic factor in gastric cancer

被引:51
作者
Mrena, Johanna [1 ]
Wiksten, Jan-Patrik [1 ]
Kokkola, Arto [1 ]
Nordling, Stig [2 ]
Ristimaki, Ari [2 ,3 ,4 ]
Haglund, Caj [1 ,2 ]
机构
[1] Univ Helsinki, Cent Hosp, Dept Surg, Helsinki 00029, Finland
[2] Univ Helsinki, Cent Hosp, Dept Pathol, Helsinki 00029, Finland
[3] Univ Oulu, Dept Pathol, Oulu, Finland
[4] Oulu Univ Hosp, Oulu, Finland
基金
芬兰科学院;
关键词
COX-2; p53; Gastric cancer; Multivariate analysis; Survival; S-PHASE FRACTION; DNA-PLOIDY; CYCLOOXYGENASE-2; EXPRESSION; COLORECTAL-CANCER; P53; ACCUMULATION; CARCINOMA; KI-67; METASTASIS; PROTEIN; CARCINOGENESIS;
D O I
10.1007/s13277-009-0001-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cyclooxygenase-2 (COX-2) is an important factor in gastric carcinogenesis, and COX-2 expression in gastric cancer patients correlates with prognosis. We have now studied the impact of COX-2 in comparison to six other tissue tumor markers, DNA index, and S-phase fraction (SPF) in a large series of gastric cancer specimens. From 342 consecutive patients, 337 archival tissue specimens were available for immunohistochemistry of COX-2, HuR, cyclin A, MMP-2, p53, p21, and Ki-67 and 313 for analysis of DNA index and S-phase fraction by flow cytometry. Associations between factors were assessed by chi-square test and survival analysis by the Kaplan-Meier method and Cox model. A significant association emerged between of COX-2 and p53 (p<0.0001), Ki-67 (p=0.013), DNA ploidy (p<0.0001), and SPF (p<0.0001). In an extended multivariate analysis, COX-2 and p53 expression were independent prognostic factors for poor survival, in addition to high stage and non-curative surgery. In gastric cancer, COX-2 expression associated with markers for apoptosis and proliferation, and furthermore, it was confirmed that COX-2 and p53 are strong prognostic indicators.
引用
收藏
页码:1 / 7
页数:7
相关论文
共 40 条
[1]   DNA aneuploidy by flow cytometry is an independent prognostic factor in gastric cancer [J].
Abad, M ;
Ciudad, J ;
Rincon, MR ;
Silva, I ;
Paz-Bouza, JI ;
Lopez, A ;
Alonso, AG ;
Bullon, A ;
Orfao, A .
ANALYTICAL CELLULAR PATHOLOGY, 1998, 16 (04) :223-231
[2]   DNA ploidy and its clinical implications in gastric cancer [J].
Baba, H ;
Korenaga, D ;
Kakeji, Y ;
Haraguchi, M ;
Okamura, T ;
Maehara, Y .
SURGERY, 2002, 131 (01) :S63-S70
[3]   The Ki-67 protein: Fascinating forms and an unknown function [J].
Endl, E ;
Gerdes, J .
EXPERIMENTAL CELL RESEARCH, 2000, 257 (02) :231-237
[4]   Lost in transcription: p21 repression, mechanisms, and consequences [J].
Gartel, AL ;
Radhakrishnan, SK .
CANCER RESEARCH, 2005, 65 (10) :3980-3985
[5]   Expression of cyclooxygenase-2, p53 and Ki-67 in gastric cancer [J].
Joo, Young-Eun ;
Chung, Ik-Joo ;
Park, Young-Kyu ;
Koh, Yang-Seok ;
Lee, Jae-Hyuk ;
Park, Chang-Hwan ;
Lee, Wan-Sik ;
Kim, Hyun-Soo ;
Choi, Sung-Kyu ;
Rew, Jong-Sun ;
Park, Chang-Soo ;
Kim, Sei-Jong .
JOURNAL OF KOREAN MEDICAL SCIENCE, 2006, 21 (05) :871-876
[6]   Expression of cyclooxygenase-2 in primary and remnant gastric carcinoma:: Comparing it with p53 accumulation, Helicobacter pylori infection, and vascular endothelial growth factor expression [J].
Kawabe, A ;
Shimada, Y ;
Uchida, S ;
Maeda, M ;
Yamasaki, S ;
Kato, M ;
Hashimoto, Y ;
Ohshio, G ;
Matsumoto, M ;
Imamura, M .
JOURNAL OF SURGICAL ONCOLOGY, 2002, 80 (02) :79-88
[7]   Metastasis-associated protein S100A4 and p53 predict relapse in curatively resected stage III and IV (M0) gastric cancer [J].
Kim, Yu Jung ;
Kim, Min A. ;
Im, Seock-Ah ;
Kim, Tae Min ;
Kim, Dong-Wan ;
Yang, Han-Kwang ;
Heo, Dae Seog ;
Lee, Kuhn-Uk ;
Choe, Kuk Jin ;
Kim, Noe Kyeong ;
Kim, Tae-You ;
Kim, Woo Ho ;
Bang, Yung-Jue .
CANCER INVESTIGATION, 2008, 26 (02) :152-158
[8]   Tissue microarrays for high-throughput molecular profiling of tumor specimens [J].
Kononen, J ;
Bubendorf, L ;
Kallioniemi, A ;
Bärlund, M ;
Schraml, P ;
Leighton, S ;
Torhorst, J ;
Mihatsch, MJ ;
Sauter, G ;
Kallioniemi, OP .
NATURE MEDICINE, 1998, 4 (07) :844-847
[9]  
KORENAGA D, 1988, CANCER-AM CANCER SOC, V62, P309, DOI 10.1002/1097-0142(19880715)62:2<309::AID-CNCR2820620214>3.0.CO
[10]  
2-#